Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Overview
Knowledge Translation Program for the guidelines and evidence-based management of PAH patients
Study Type
- Study Type: Observational [Patient Registry]
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: April 10, 2018
Detailed Description
To improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (defined as: 1) improvement of FC III or IV to FC II; 2) improvement of FC II to FC I; or 3) maintaining FC II or I)
Interventions
- Drug: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Arms, Groups and Cohorts
- Standard of care
- Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
Clinical Trial Outcome Measures
Primary Measures
- Patients achieving guideline-recommended treatment
- Time Frame: 3 years
- Proportion of patients achieving guideline-recommended treatment
Secondary Measures
- Patients achieving optimal functional class
- Time Frame: 3 years
- Proportion of patients achieving optimal functional class using an evidence-based treatment algorithm
Participating in This Clinical Trial
Inclusion Criteria
1. Male and female adults (≥ 18 years of age) 2. Documented diagnosis of PAH (all of the following): i. RHC demonstrating mPAP > 25 mm Hg and PCWP ≤ 15 and PVR > 3 ii. FEV 1 > 50% predicted normal iii. V/Q and/or CT scan excluding the thromboembolic etiology 3. Diagnosis of PAH < 3 years 4. Need for PAH specific treatment 5. Desire to participate and signs an informed consent Exclusion Criteria:
Any of the criteria below: 1. Poor mental function, drug or substance (e.g.,alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study 2. Prior participation in this program 3. Patients with pulmonary hypertension classified as group 2 – 5 Updated Clinical Classification of Pulmonary Hypertension (5th World Symposium on PH Modified Classification of PH)
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Actelion
- Collaborator
- Canadian Heart Research Centre
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Vallerie McLaughlin, MD, Study Chair, University of Michigan
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.